Published On: Wed, Oct 19th, 2016

Luminex Corporation (NASDAQ:LMNX) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Luminex Corporation (NASDAQ:LMNX).

Most recent broker ratings

10/12/2016 – Avondale Partners began new coverage on Luminex Corporation giving the company a “outperform” rating. They now have a USD 27 price target on the stock.

08/18/2016 – Luminex Corporation was upgraded to “neutral” by analysts at JP Morgan. They now have a USD 22 price target on the stock.

05/03/2016 – Luminex Corporation had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 20 price target on the stock.

11/03/2015 – Luminex Corporation had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 21 price target on the stock.

11/03/2015 – Luminex Corporation had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 21 price target on the stock.

10/12/2015 – Luminex Corporation had its “market perform” rating reiterated by analysts at William Blair.

08/04/2015 – Luminex Corporation was upgraded to “outperform” by analysts at Wedbush. They now have a USD 22 price target on the stock.

07/01/2015 – Luminex Corporation had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 18 price target on the stock.

03/24/2015 – Luminex Corporation had its “buy” rating reiterated by analysts at Zacks. They now have a USD 18 price target on the stock.

10/28/2014 – Luminex Corporation was downgraded to “equal weight” by analysts at Stephens.

10/09/2014 – Citigroup began new coverage on Luminex Corporation giving the company a “neutral” rating.

The share price of Luminex Corporation (NASDAQ:LMNX) was up +0.96% during the last day of trading, with a day high of 22.19. 97102 shares were traded during the last session.

The stock’s 50 day moving average is 22.11 and its 200 day moving average is 21.05. The stock’s market capitalization is 961.98M. Luminex Corporation has a 52-week low of 17.29 and a 52-week high of 23.75.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.